MedPath

Tagged News

Vgenomics Partners with Dr. Shroff's Eye Hospital to Validate AI-Powered Tear Biomarker for Early Keratoconus Detection

AI
  • Vgenomics and Dr. Shroff's Charity Eye Hospital have collaborated to validate VSP-2224, a novel tear-based biomarker for early keratoconus detection using AI technology and the RgenX-LENS platform.
  • The non-invasive biomarker can detect keratoconus before symptoms appear, potentially enabling earlier intervention than current diagnostic methods that only work after significant corneal damage occurs.
  • More than 2% of India's population is estimated to be affected by keratoconus, with the disease also spreading rapidly in MENA countries, highlighting the urgent need for accessible early detection methods.
  • Vgenomics is developing OcuTear, a point-of-care diagnostic kit for surface eye diseases, with VSP-2224 serving as the key marker for keratoconus detection.

John Snow Labs Acquires WiseCube to Enhance Medical AI with Billion-Scale Knowledge Graphs

AIDrug Discovery
  • John Snow Labs has acquired WiseCube, a pioneer in biomedical knowledge graphs and AI-powered literature analysis, to strengthen its healthcare AI solutions with billion-scale knowledge platform capabilities.
  • The acquisition will enable enhanced biomedical literature review through unique algorithms that analyze unstructured data and medical ontologies to generate new scientific hypotheses.
  • WiseCube's technology will accelerate drug discovery by surfacing hidden relationships among drugs, genes, and diseases, shortening the path from discovery to clinical trials.
  • The integration includes WiseCube's Pythia service with hallucination detection tools to monitor AI-generated responses for alignment with verified medical knowledge, improving safety and compliance of medical AI applications.

MAXIOM Launches AI-Powered Health Coach Platform, Enters Clinical Trials to Validate Performance Against Human Experts

AIPrecision Medicine
  • MAXIOM officially launched its AI platform that integrates DNA analysis, biomarkers, wearables, and artificial intelligence to deliver personalized health and performance guidance through conversational interactions.
  • The company secured $2M in seed funding led by Conscious Ventures and investment from genetics firm DNAthlete, while opening a $6M Series A round to scale the platform globally.
  • A randomized double-blind clinical trial launching in June will compare MAXIOM's AI coaching strategies against human coaching techniques to demonstrate the platform's effectiveness.
  • Three World Champions including Olympic champion Kristian Blummenfelt have adopted the platform, with some athletes replacing their human coaches entirely and relying on AI guidance for training optimization.

CurifyLabs Secures €6.7M to Automate Personalized Medicine Manufacturing with AI-Driven Platform

AI
  • CurifyLabs raised €6.7 million led by Springvest to advance automated manufacturing of compounded medications for patients with specific individual needs.
  • The company's Compounding System Solution makes the manufacturing process four times faster while enabling limitless dosing flexibility through desktop-sized robotic technology.
  • CurifyLabs launched RoboPharma, a €5.6 million EU-funded initiative to create a decentralized pharmaceutical manufacturing platform using AI and robotics.
  • The global compounded medications market is valued at €15 billion and growing at 5.5% annually, driven by aging populations and supply chain challenges.

Teva and Biolojic Design Launch IND-Enabling Studies for Dual-Target BD9 Antibody in Inflammatory Diseases

AI
  • Teva Pharmaceutical Industries has initiated investigational new drug (IND)-enabling studies for BD9, a dual-specific multibody targeting both TSLP and IL-13 for treating TH2-driven inflammatory conditions including atopic dermatitis and asthma.
  • The BD9 multibody was designed using Biolojic Design's computational biology and artificial intelligence platform, representing the fourth antibody from this next-generation platform to reach or near clinical development.
  • Under an exclusive licensing agreement, Teva will lead global development of BD9 while Biolojic is eligible for milestone payments based on pre-clinical, clinical, regulatory, and commercial achievements.
  • Separately, the FDA granted fast track designation to Teva's TEV-53408, an anti-IL-15 antibody for treating celiac disease in patients following a gluten-free diet.

BostonGene Presents Six AI-Driven Cancer Research Studies at 2025 ASCO Annual Meeting

AIPrecision Medicine
  • BostonGene will present six accepted abstracts at the 2025 ASCO Annual Meeting, demonstrating its multimodal AI platform's capabilities in oncology drug development.
  • The studies showcase novel biomarker discovery across multiple cancer types including sarcoma, breast cancer, liposarcoma, and non-small cell lung cancer.
  • Research conducted in collaboration with MD Anderson Cancer Center reveals new insights into tumor microenvironment profiling and therapeutic response prediction.
  • The company's Tumor Portrait™ test identified distinct molecular patterns that correlate with survival outcomes across various cancer subtypes.

Lunit Presents 12 AI-Powered Studies at ASCO 2025, Demonstrating Enhanced Cancer Treatment Selection

AIOncology
  • Lunit will present 12 studies at ASCO 2025 showcasing AI-powered digital pathology solutions for precision oncology applications.
  • A key study with Japan's National Cancer Center demonstrated AI-enhanced HER2 analysis in biliary tract cancer, identifying additional responders to trastuzumab deruxtecan with 50% objective response rate.
  • AI-powered PD-L1 evaluation showed 70% concordance with expert pathologists and identified 231 additional immunotherapy candidates among 949 lung cancer patients.
  • Research includes novel AI models for predicting CLDN18.2 expression in gastric cancer and comprehensive tumor microenvironment analysis across multiple cancer types.

Madras Diabetes Research Foundation Partners with Russia's Almazov Centre for AI-Driven Diabetes Research

AIPrecision Medicine
  • The Madras Diabetes Research Foundation (MDRF) has signed a strategic MoU with Russia's Almazov National Medical Research Centre to advance diabetes research through international collaboration.
  • The partnership will focus on developing new diagnostics and treatment strategies for diabetes, with particular emphasis on gestational diabetes mellitus (GDM).
  • Both institutions will explore artificial intelligence and precision medicine applications in diabetes care, marking a significant step toward technology-driven therapeutic approaches.
  • The collaboration includes joint research projects, academic exchanges, training programs, and shared publications between the Chennai-based foundation and the Saint Petersburg medical center.

Insilico Medicine Predicts First AI-Designed Drugs to Reach Market by 2030

AIDrug Discovery
  • Insilico Medicine CEO Alex Zhavoronkov predicts the first fully AI-designed drugs could be available to patients within five to six years, marking a potential breakthrough in pharmaceutical development.
  • The company has developed 22 clinical-stage candidates using its end-to-end AI platform, with one idiopathic pulmonary fibrosis drug showing a 98 mL increase in lung capacity over placebo in Phase I trials.
  • Insilico has achieved unprecedented development timelines, with their fastest candidate reaching clinical stage in just nine months compared to the traditional 12-year drug development cycle.
  • The company has successfully out-licensed three AI-generated drug candidates to pharmaceutical partners, earning several hundred million dollars and validating the commercial viability of AI-driven drug discovery.

SeqOne Genomics Secures €20 Million to Accelerate AI-Powered NGS Platform for Personalized Medicine

AIOncology
  • SeqOne Genomics raised €20 million in an oversubscribed growth round led by Supernova Invest to advance its AI-driven genomic analysis platform for clinical diagnostics.
  • The French company has achieved remarkable growth with 140 laboratory customers across 22 countries and expects to process over 110,000 patient analyses in 2025.
  • Funding will support global expansion, U.S. market acceleration following Q1 2025 launch, and strategic acquisitions to enhance multi-omics capabilities.
  • SeqOne's platform provides clinical decision-support tools for oncology and rare disease applications, positioning the company as a European leader in NGS data interpretation.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.